S. H. Swerdlow, World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 2008.

M. Dreyling, Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med

J. G. Gribben, How I treat indolent lymphoma, Blood, vol.109, issue.11, pp.4617-4626, 2007.
DOI : 10.1182/blood-2006-10-041863

W. T. Swenson, Improved Survival of Follicular Lymphoma Patients in the United States, Journal of Clinical Oncology, vol.23, issue.22, pp.5019-5026, 2005.
DOI : 10.1200/JCO.2005.04.503

D. Pulte, A. Gondos, and H. Brenner, Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008???2012, Cancer Epidemiology, vol.36, issue.1, pp.19-25, 2012.
DOI : 10.1016/j.canep.2011.08.006

S. M. Smith, Dissecting follicular lymphoma: high versus low risk, Hematology, vol.2013, issue.1, pp.561-567, 2013.
DOI : 10.1182/asheducation-2013.1.561

P. Solal-céligny, Follicular Lymphoma International Prognostic Index, Blood, vol.104, issue.5, pp.1258-1265, 2004.
DOI : 10.1182/blood-2003-12-4434

M. Federico, Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project, Journal of Clinical Oncology, vol.27, issue.27, pp.4555-4562, 2009.
DOI : 10.1200/JCO.2008.21.3991

P. Brice, Comparison in low-tumor-burden follicular lymphomas between an initial notreatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte, J. Clin. Oncol. Off. J

G. Salles and H. Ghesquières, Current and future management of follicular lymphoma, International Journal of Hematology, vol.24, issue.2
DOI : 10.1007/s12185-012-1202-y

W. Hiddemann and B. D. Cheson, How we manage follicular lymphoma, Leukemia, vol.23, issue.7, 2014.
DOI : 10.1038/leu.2014.91

G. Salles, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7

C. Sebban, Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study, Journal of Clinical Oncology, vol.26, issue.21
DOI : 10.1200/JCO.2007.15.5358

L. Gouill and S. , Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study, Haematologica, vol.96, issue.8, pp.1128-1135, 2011.
DOI : 10.3324/haematol.2010.030320

G. G. Laport, Changing role of stem cell transplantation in follicular lymphoma, Hematol

E. Bachy and G. Salles, Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL, Best Practice & Research Clinical Haematology, vol.24, issue.2, pp.257-270, 2011.
DOI : 10.1016/j.beha.2011.03.001

URL : https://hal.archives-ouvertes.fr/ensl-00808492

S. Montoto, Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party, Haematologica, vol.98, issue.7, pp.1014-1021, 2013.
DOI : 10.3324/haematol.2013.084723

C. Phipps, Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity, Leukemia & Lymphoma, vol.116, issue.1, 2014.
DOI : 10.1200/JCO.2012.47.1862

J. Trotman, Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET- 63, p.65

S. Luminari, The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL), Annals of Oncology, vol.25, issue.2
DOI : 10.1093/annonc/mdt562

J. Dupuis, F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High???Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS, Journal of Clinical Oncology, vol.30, issue.35, pp.4317-4322, 2012.
DOI : 10.1200/JCO.2012.43.0934

A. J. Moskowitz, Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, vol.116, issue.23, pp.4934-4937, 2010.
DOI : 10.1182/blood-2010-05-282756

D. Decaudin, 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.2, pp.212-218, 2011.
DOI : 10.1016/j.clml.2011.03.007

B. D. Cheson, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J. Clin. Oncol. Off. J

B. D. Cheson, Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5
DOI : 10.1200/JCO.2006.09.2403

M. Meignan, A. Gallamini, M. Meignan, A. Gallamini, and C. Haioun, Report on the First International Workshop on interim-PET scan in lymphoma, Leukemia & Lymphoma, vol.50, issue.8, pp.1257-1260, 2009.
DOI : 10.1007/s00259-008-0787-0

C. Lin, Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis, Journal of Nuclear Medicine, vol.48, issue.10
DOI : 10.2967/jnumed.107.042093

P. Peduzzi, J. Concato, A. R. Feinstein, and T. R. Holford, Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates, Journal of Clinical Epidemiology, vol.48, issue.12, pp.1503-1510, 1995.
DOI : 10.1016/0895-4356(95)00048-8

M. Federico, R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi, Journal of Clinical Oncology, vol.31, issue.12, pp.1506-1513, 2013.
DOI : 10.1200/JCO.2012.45.0866

C. Tychyj-pinel, PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study, European Journal of Nuclear Medicine and Molecular Imaging, vol.71, issue.3, pp.408-415, 2014.
DOI : 10.1007/s00259-013-2441-8

URL : https://hal.archives-ouvertes.fr/hal-01141154

M. E. Juweid, Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.571-578, 2007.
DOI : 10.1200/JCO.2006.08.2305

E. Itti, Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background, Journal of Nuclear Medicine, vol.51, issue.12, pp.1857-1862, 2010.
DOI : 10.2967/jnumed.110.080556

R. D. Gentzler, F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma, British Journal of Haematology, vol.11, issue.6, 2014.
DOI : 10.1111/bjh.12824

E. Itti, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ??SUVmax, European Journal of Nuclear Medicine and Molecular Imaging, vol.119, issue.Suppl 1
DOI : 10.1007/s00259-013-2435-6

S. Luminari, The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi, Annals of Oncology, vol.24, issue.8, pp.2108-211265, 2013.
DOI : 10.1093/annonc/mdt137

P. Brice, High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol, Annals of Oncology, vol.11, issue.12, pp.1585-1590, 2000.
DOI : 10.1023/A:1008399623564

H. C. Schouten, High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin???s Lymphoma: Results From the Randomized European CUP Trial, Journal of Clinical Oncology, vol.21, issue.21
DOI : 10.1200/JCO.2003.10.023

B. Metzner, Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation, Annals of Oncology, vol.24, issue.6
DOI : 10.1093/annonc/mds657

J. Kothari, Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project, Br. J. Haematol, 2014.

A. K. Gopal, PI3K?? Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma, New England Journal of Medicine, vol.370, issue.11, pp.1008-1018, 2014.
DOI : 10.1056/NEJMoa1314583

J. R. Westin, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, p.trial
DOI : 10.1016/S1470-2045(13)70551-5

R. Pettengell, Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, Journal of Clinical Oncology, vol.31, issue.13
DOI : 10.1200/JCO.2012.47.1862